Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Retatrutide is a triple-receptor agonist targeting GLP-1, GIP, and glucagon pathways simultaneously, producing an average of 24.2% body weight reduction in Phase 2 clinical trials at the 12mg dose
A 2025 pilot study infused up to 20 mg of BPC157 intravenously in 2 healthy adults and reported no adverse effects and no abnormal changes in heart, liver, kidney, thyroid, or bloodglucose markers
Related resources: PT-141 Profile Melanotan II Dosage Protocol What it does: Melanotan II produces a deep tan without UV exposure (or with minimal sun)
In the United States, injectable GHK-Cu is not an FDA-approved finished drug for any indication
US$ 25.81
US$ 26.17
US$ 21.16
US$ 23.76
US$ 22.58
US$ 27.33
US$ 22.07
US$ 27.22
US$ 26.76
